Mesoblast (MESO) - P/S ratio

P/S ratio at the end of 2026: 14.2

According to Mesoblast 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 3.18. At the end of 2026 the company had a P/S ratio of 14.2.

P/S ratio history for Mesoblast from 2009 to 2026

PS ratio at the end of each year

Year	P/S ratio	Change
2026	14.2	-82.41%
2025	80.6	-38.76%
2024	132	55.24%
2023	84.8	217.34%
2022	26.7	-79.37%
2021	130	214.08%
2020	41.2	34.86%
2019	30.6	0.91%
2018	30.3	-91.32%
2017	349	4629.98%
2016	7.38	-84.83%
2015	48.7	-14.71%
2014	57.1	6.41%
2013	53.6	112.72%
2012	25.2	112.8%
2011	11.8	-96.28%
2010	318	-34.98%
2009	490

P/S ratio for similar companies or competitors

Company	P/S ratio	P/S ratio differencediff.	Country
Nymox Pharmaceutical NYMX	N/A	N/A	Bahamas
NRC Health NRC	3.19	-98.68%	🇺🇸 USA

What is the market capitalization of a company?

The market capitalization sometimes referred as Marketcap, is the value of a publicly listed company.
In most cases it can be easily calculated by multiplying the share price with the amount of outstanding shares.

DISCLAIMER

CompaniesMarketCap is not associated in any way with CoinMarketCap.com
Stock prices are delayed, the delay can range from a few minutes to several hours.
Company logos are from the CompaniesLogo.com logo database and belong to their respective copyright holders. Companies Marketcap displays them for editorial purposes only.

Contact

For inquiries or if you want to report a problem write to hello@8marketcap.com

Links

- Privacy policy

- Terms and conditions

P/S ratio for Mesoblast (MESO)

P/S ratio at the end of 2026: 14.2